TACE by using arsenic trioxide drug-bearing CalliSpheres beads for the treatment of BCLC stage B HCC: preliminary results in 13 patients
10.3969/j.issn.1008-794X.2019.03.006
- VernacularTitle:TACE术中应用三氧化二砷CalliSpheres载药栓塞微球治疗BCLC B期原发性肝癌13例
- Author:
Yahua LI
1
;
Xuhua DUAN
;
Xinwei HAN
;
Jianzhuang REN
;
Zhen LI
;
Pengfei CHEN
Author Information
1. 郑州大学第一附属医院放射介入科 450052
- Keywords:
arsenic trioxide;
CalliSpheres bead;
primary hepatocellular carcinoma;
transcatheter arterial chemoembolization;
drug-bearing microsphere
- From:
Journal of Interventional Radiology
2019;28(3):232-236
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinic effect of transcatheter arterial chemoembolization (TACE) by using arsenic trioxide (ATO) drug-bearing CalliSpheres beads (CB) in treating BCLC stage B hepatocellular carcinoma (HCC) . Methods The clinical data of 13 patients with advanced HCC, who received TACE by using CB loaded with ATO (CBATO) during the period from January 2017 to September 2017, were retrospectively analyzed. The clinical data, imaging materials, laboratory examinations, interventional complications, prognosis, etc., were summarized and evaluated. Results The patients were followed up for9-15 months, with a median period of 11 months. The survival rate was 100％. One, 3, 6 and 9 months after treatment, the disease remission (CR+PR) rates were 76.9％, 76.9％, 69.2％ and 61.5％ respectively, and the disease control rates were 92.3％, 92.3％, 92.3％ and 84.6％ respectively. In all 13 patients, no severe complications such as hepatic failure, renal insufficiency, bone marrow suppression, liver abscess, bile leakage complicated by infection and gastrointestinal bleeding occurred. Conclusion For the treatment of BCLC stage B HCC, TACE by using CBATO is safe and effective with reliable short-term effect.
